Sector News

Fat could hold key to stem cell treatments for Parkinson’s disease

June 5, 2022
Life sciences

Could fat hold the key to finally treating Parkinson’s disease? A study by researchers at Harvard Medical School and Massachusetts General Hospital has suggested that fatty tissue could produce a source of homegrown stem cells needed to create long-sought-after regenerative treatments for a range of central nervous system disorders.

These neural stem cells were first identified while scientists were examining subcutaneous adipose tissue (SAT), otherwise known as body fat, in mice and noticed that a clump of nerve fibers included what appeared to be Schwann cells, a type of cell involved in the maintenance and regeneration of the motor and sensory neurons of the peripheral nervous system. Further in vitro analysis of these Schwann cells showed they can develop stem-cell-like qualities, according to a study published May 25 in Science Translational Medicine.

The researchers noted that when the cells were grafted into the gastrointestinal tracts of mice, they differentiated into both neurons and supportive glial cells, which provide physical and metabolic support to neurons. What’s more, the Schwann cells were shown to have regenerative properties, improving digestive function in mice with digestive disorders like gastroparesis and colonic aganglionosis.

But their potential benefits don’t stop at the stomach—the researchers pointed out that the main barrier to developing effective treatments for the likes of Parkinson’s and stroke has been sourcing neural stem cells from the patient’s own body.

“Because adipose stem cells are widely considered to be safe therapeutic agents for humans … the derivation of SAT-[neural stem cells] offers unprecedented potential for therapeutic application in neurological diseases,” the researchers said.

Before that, more work is required to define the properties of these cells and establish protocols to isolate and expand them, they added.

By Max Bayer, James Waldron

Source: fiercebiotech.com

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.